Opendata, web and dolomites

Promitil

Promitil® - a new ‘smart’ nanomedicine for cancer chemo-radiotherapy.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Promitil" data sheet

The following table provides information about the project.

Coordinator
LIPOMEDIX PHARMACEUTICALS LTD 

Organization address
address: HI-TECH PARK BLDG 4 5 HU GIV AT RAM CAMPUS
city: JERULASEM
postcode: 9139102
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.lipomedix.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIPOMEDIX PHARMACEUTICALS LTD IL (JERULASEM) coordinator 50˙000.00

Map

 Project objective

There were over 18M new cases of cancer worldwide in 2018, out of which about 3.7M were in Europe. To treat cancer, radiotherapy is increasingly used in combination with chemotherapy. Chemo-radiotherapy is a non-invasive approach for cancer local control, given within a reduced period time and with potential for complete cure of cancer. The key to enabling the full potential of chemo-radiotherapy depends on radio-sensitization, which means the degree of effectiveness of the anti-cancer agents used for chemotherapy that make tumour cell more sensitive to radiation therapy. However, radio-sensitizers, like Mitomycin-C (MMC), still need to be significantly improved to achieve a more effective and safe treatment of patients.

LipoMedix has developed a novel nanomedicine (Promitil® ) for chemo-radiotherapy. It is a liposome formulation of a Mitomycin-C Lipid-based (MLP) prodrug of the anticancer agent MMC. Promitil® enables efficient delivery of MLP with rapid activation in tumour tissue, yet with improved safety profile because it becomes active only upon radiation. This results in a higher and safer radio-sensitization effect.

LipoMedix is an Israeli pharma SME founded in 2011. Its team has been involved for more than 20 years in cancer drugs and therapies, and now its mission is deliver to a novel, efficient, and side-effect free liposome prodrug to improve patients’ quality of life, healthcare outcomes and reduce the economic healthcare stress of chemo-radiotherapy.

The SME-I Phase 1 project perfectly suits the innovation’s current stage of development and overall business strategy allowing LipoMedix to check final specifications of Promitil®, establish sound business development and gain partners necessary for the Phase II study.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROMITIL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROMITIL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

Cortx (2019)

Intelligent debt recovery platform.

Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More